









Markets
/
Stocks
/
nasdaq-jnj
/

Johnson & Johnson

JNJ

190.400USD

-2.020-1.05%

Close 10/24, 16:00（ET）Quotes delayed by 15 min

458.14BMarket Cap

18.24P/E TTM



Johnson & Johnson

190.400

-2.020-1.05%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Johnson & Johnson

Currency: USD Updated: 2025-10-24

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Johnson & Johnson's Score

Industry at a Glance

Industry Ranking

25 / 173

Overall Ranking

68 / 4683

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 27 analysts

Buy

Current Rating

199.059

Target Price

+3.42%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Johnson & Johnson Highlights

StrengthsRisks

Johnson & Johnson is an American multinational corporation specializing in pharmaceuticals, biotechnology, and medical technologies, headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange (NYSE:JNJ). Its common stock is part of the Dow Jones Industrial Average, and the company is ranked No. 42 on the 2024 Fortune 500 list of the largest corporations in the United States. In 2024, it was ranked 45th on the Forbes Global 2000 list. Johnson & Johnson employs approximately 138,000 individuals globally, led by its current chairman and CEO, Joaquin Duato.

Founded in 1886 by three brothers—Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson—the company initially focused on selling ready-to-use sterile surgical dressings. In 2023, the firm spun off its consumer healthcare business segment into a new publicly traded entity, Kenvue, allowing it to concentrate solely on the development and manufacturing of pharmaceutical prescription drugs and medical device technologies.

Johnson & Johnson is recognized as one of the most valuable companies worldwide and is one of only two U.S.-based corporations possessing a prime credit rating of AAA.

Industry Leader

The company's revenue leads the industry, with the latest annual revenue totaling USD 88.82B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 84.05%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 84.05%.

Fairly Valued

The company’s latest PE is 18.25, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.80B shares, increasing 0.00% quarter-over-quarter.

Held by Donald Yacktman

Star Investor Donald Yacktman holds 1.36M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-24

The company's current financial score is 7.94, which is higher than the Pharmaceuticals industry's average of 7.77. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 23.99B, representing a year-over-year increase of 6.77%, while its net profit experienced a year-over-year increase of 91.24%.

Score

Industry at a Glance

Previous score

7.94

Change



Financials

8.02

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.09

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

8.31

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.53

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.75

Key Metrics

Free cash flow

No Data

Johnson & Johnson's Company Valuation

Currency: USD Updated: 2025-10-24

The company’s current valuation score is 7.77, which is higher than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is 18.25, which is 91.40% below the recent high of 34.92 and 48.12% above the recent low of 9.47.

Score

Industry at a Glance

Previous score

7.77

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 25/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-24

The company’s current earnings forecast score is 7.48, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Johnson & Johnson is 203.50, with a high of 225.00 and a low of 155.00.

Score

Industry at a Glance

Previous score

7.48

Change

Support & Resistance

No Data

Analyst Rating

Based on 27 analysts

Buy

Current Rating

199.059

Target Price

+3.42%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

181

Total

Median

Average

Company name

Ratings

Analysts

Johnson & Johnson

JNJ

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-24

The company’s current price momentum score is 9.09, which is higher than the Pharmaceuticals industry's average of 7.02. Sideways: Currently, the stock price is trading between the resistance level at 196.65 and the support level at 181.97, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.42

Change

-0.33

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.704

Neutral

RSI(14)

60.532

Neutral

STOCH(KDJ)(9,3,3)

65.523

Sell

ATR(14)

3.107

Low Volatility

CCI(14)

-27.610

Neutral

Williams %R

35.355

Buy

TRIX(12,20)

0.311

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

192.282

Sell

MA10

191.967

Sell

MA20

189.796

Buy

MA50

182.300

Buy

MA100

171.574

Buy

MA200

163.669

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-24

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 74.54%, representing a quarter-over-quarter increase of 0.88%. The largest institutional shareholder is The Vanguard, holding a total of 236.03M shares, representing 9.80% of shares outstanding, with 1.79% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

236.03M

+1.31%

State Street Investment Management (US)

132.80M

-0.74%

BlackRock Institutional Trust Company, N.A.

129.76M

+0.48%

Geode Capital Management, L.L.C.

60.61M

+2.06%

JP Morgan Asset Management

36.71M

+4.13%

State Farm Insurance Companies

34.37M

Norges Bank Investment Management (NBIM)

31.93M

+5.18%

Morgan Stanley Smith Barney LLC

25.30M

+5.13%

Wellington Management Company, LLP

24.88M

+9.85%

BlackRock Asset Management Ireland Limited

19.85M

+0.75%

Risk Assessment

Currency: USD Updated: 2025-10-24

The company’s current risk assessment score is 9.95, which is higher than the Pharmaceuticals industry's average of 5.11. The company's beta value is 0.37. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.